These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25244542)

  • 1. KRAS and BRAF mutations in anal carcinoma.
    Serup-Hansen E; Linnemann D; Høgdall E; Geertsen PF; Havsteen H
    APMIS; 2015 Jan; 123(1):53-9. PubMed ID: 25244542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.
    Bidinotto LT; Véo CA; Loaiza EA; De França AP; Lorenzi AT; Rosa LA; De Oliveira CM; Levi JE; Scapulatempo-Neto C; Longatto-Filho A; Reis RM
    Mol Med Rep; 2016 Oct; 14(4):3791-7. PubMed ID: 27573925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).
    Casadei Gardini A; Capelli L; Ulivi P; Giannini M; Freier E; Tamberi S; Scarpi E; Passardi A; Zoli W; Ragazzini A; Amadori D; Frassineti GL
    PLoS One; 2014; 9(3):e92071. PubMed ID: 24642661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
    Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
    Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
    Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
    Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS and BRAF mutations in sinonasal cancer.
    López F; García Inclán C; Pérez-Escuredo J; Alvarez Marcos C; Scola B; Suárez C; Llorente JL; Hermsen MA
    Oral Oncol; 2012 Aug; 48(8):692-7. PubMed ID: 22459936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
    Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
    Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
    Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
    J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
    Shigaki H; Baba Y; Watanabe M; Miyake K; Murata A; Iwagami S; Ishimoto T; Iwatsuki M; Yoshida N; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S485-91. PubMed ID: 23274581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
    Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
    BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.
    Martin V; Zanellato E; Franzetti-Pellanda A; Molinari F; Movilia A; Paganotti A; Deantonio L; De Dosso S; Assi A; Crippa S; Boldorini R; Mazzucchelli L; Saletti P; Frattini M
    Histol Histopathol; 2014 Apr; 29(4):513-21. PubMed ID: 24122611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.